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Abstract: The objective of this article is to review the basis supporting the usefulness of melatonin
as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high
risk for this disease. Melatonin, as a result of its antiestrogenic and antioxidant properties, as well
as its ability to improve the efficacy and reduce the side effects of conventional antiestrogens, could
safely be associated with the antiestrogenic drugs presently in use. In individuals at risk of BC due
to night shift work, the light-induced inhibition of melatonin secretion, with the consequent loss of
its antiestrogenic effects, would be countered by administering this neurohormone. BC risk from
exposure to metalloestrogens, such as cadmium, could be treated with melatonin supplements to
individuals at risk of BC due to exposure to this xenoestrogen. The BC risk related to obesity may be
reduced by melatonin which decrease body fat mass, inhibits the enhanced aromatase expression
in obese women, increases adiponectin secretion, counteracts the oncogenic effects of elevated
concentrations of leptin; and decreases blood glucose levels and insulin resistance. Despite compelling
experimental evidence of melatonin’s oncostatic actions being susceptible to lowering BC risk, there is
still a paucity of clinical trials focused on this subject.
Keywords: melatonin; breast cancer risk; antiestrogens; light-at-night; shift work; metalloestrogens;
cadmium; obesity
1. Introduction
1.1. Breast Cancer (BC) Risk
Breast cancer is one of the most common neoplasias in women, with about 1.7 million new cases
diagnosed worldwide in 2012, representing about 25% of all cancer cases in women, and is the second
leading cause of cancer deaths in developed countries [1]. In men, the number of new cases expected to
be diagnosed in the USA during 2017 is approximately 2470 [2]. As a result of significant advances in
its diagnosis and treatment, the mortality rate for BC is lower than that of its incidence [1]. An increased
understanding of the etiology and pathogenesis of BC has allowed the definition of populations who
are at high risk for developing this kind of tumor. The National Cancer Institute, in its PDQ Cancer
Information Summary published on 28 July 2017, listed the following factors as having “adequate
evidence of increased risk of breast cancer”: gender and advanced age, endogenous estrogens,
gene mutations (inherited risk), combination hormone therapy (estrogen-progestin), exposure to
ionizing radiation, high breast density, obesity and alcohol consumption [3]. As a consequence of the
definition of BC risk factors, the search for preventive therapies for this pathology is an expanding
field in medical research. Included among the interventions considered to present “adequate evidence
of benefit” are chemical treatments (selective estrogen receptor modulators or aromatase inhibitors)
and surgical interventions such as prophylactic mastectomy and oophorectomy [3,4]. Obviously,
the periodic monitoring of at risk patients is part of the prevention strategies [5].
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1.2. Melatonin
Melatonin is an indoleamine secreted mainly by the pineal gland with circadian rhythmicity.
This molecule exerts regulatory actions on multiple physiological functions. For example, melatonin
is involved in the modulation of the neuroendocrine reproductive axis, the metabolism of lipids
and carbohydrates, the rhythm of body temperature, the sleep/wake rhythm, the oxidative
status, etc. [6–9]. From numerous experimental studies carried out in rodents it has been demonstrated
that melatonin prevents the promotion and growth of both spontaneous and chemically induced
mammary tumors [10–15]. Furthermore, in vitro, melatonin, at physiological concentrations, inhibits
cell proliferation and invasiveness in human breast cancer cells [14,16]. However, despite mounting
evidence supporting melatonin actions that relate to BC treatment [17,18], its clinical use in BC therapy,
either as the main drug or as an adjuvant therapy in conjunction with other drugs, has only been
assayed on a few occasions and these have been mainly related not to the suppression of tumor growth
but rather with the relief of symptoms associated with the tumoral process, such as improvement of
sleep and life quality [19], treatment of depressive symptoms and anxiety [20], prevention of breast
radiation dermatitis [21] or to decrease the toxicity and to increase the efficacy of chemotherapy [22].
It is conceivable that the success of the current hormonal therapies for estrogen receptor positive (ER+)
breast cancer, enhanced with the new generations of ER degraders, inhibitors of PI3k, AKT, etc. [23],
as well as the effectiveness of new therapeutic strategies for the treatment of triple negative tumors [24],
together with the improvement of the classic chemo and radiotherapeutic approaches, are among the
reasons that have thus far discouraged the staging of clinical trials to assess the value of melatonin
for BC treatment. Another reason might be that what oncologists are actually looking for are drugs
which act on molecular targets with high specificity, whereas the antitumoral effects of melatonin
are mainly based on its ability to modulate general functions (i.e., circadian rhythmicity, oxidative
status, or estrogenic levels) [17,18]. Currently, ten clinical trials examining the therapeutic value of
melatonin in BC are listed in the ClinicalTrials.gov. database. Five of them are focused on the relief of
symptoms associated with the tumoral process. The remaining five studies examine the therapeutic
effects of melatonin either alone (two trials) or as an adjuvant therapy associated to metformin, vitamin
D, fluorouracil, doxorubicin or toremifene (three trials) in women already diagnosed with BC, with the
results still being analyzed.
1.3. Objectives
The aim of this article is to review the evidence that supports the usefulness of melatonin, not for
BC treatment, but rather as an adjuvant preventive therapy for BC in several groups of individuals at
high risk for this disease. In this review we will attempt to demonstrate that there is ample evidence
which suggests that melatonin could be an efficient complement in at least the following situations:
(1) where the reduction of BC risk is based on treatment with antiestrogenic drugs; (2) when the risk
of BC depends on environmental factors such as chronodisruption due to exposure to light at night
(i.e. night shift work) or the exposure to contaminants such as xenoestrogens and, (3) in BC risk cases
related to obesity.
2. Melatonin as a Possible Adjuvant Therapy When the Reduction of BC Risk is Based on
Treatment with Antiestrogenic Drugs
2.1. The Role of Estrogens in BC
About 70% of all breast cancers express estrogen-receptors (ER+) and circulating concentrations
of estrogens are positively associated with an increased risk of BC in premenopausal women [25].
The particular role of estrogens in the physiopathology of breast cancer explains why chemoprevention
using any drug able to antagonize their actions would be taken into consideration [5]. The influence of
estrogens on mammary tissue depends on the circulating levels of estradiol and other steroids as well
as on their local concentration in mammary tissue.
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While the main source of estrogens in premenopausal women is the ovaries, in postmenopausal
women adrenal androgens and sulfated estrogens are the primary circulating steroids, and these
steroids are converted into active estrogens by enzymatic processes in the mammary tissue. Figure 1
depicts the basic enzymatic mechanisms involved in the transformation of steroids in the mammary
gland [26]. Aromatases are enzymes that transform androgens (testosterone and androstenedione) into
estrogens (estrone and 17β-estradiol) [27]. These estrogens, due to the action of estrogen sulfatases
and estrogen sulfotransferases may be in two different forms: sulfated or not sulfoconjugated.
Estrogen sulfates can serve to form active (non-sulfated) estrogens [28]. Another family of enzymes,
the 17β-hydroxysteroid dehydogenases types I and II, catalyzes the conversion of low activity steroids
(androstenedione and estrone) into high activity steroids (testosterone and 17β-estradiol respectively)
(see Figure 1) [29,30]. Contrary to what happens in normal mammary tissue, in breast cancer, the local
production of steroids is biased toward the production of the more active forms (a fact indicated by
the thickness of the arrows in Figure 1) [26].
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probably the most widely used drug in BC prevention. The results of different clinical trials in 
women classified as having a high risk for BC showed that treatment with tamoxifen (20 mg/day) for 
5 years significantly reduced the incidence of ER+ BC, but not of ER− tumors [4,31]. Flushes, as well 
as increased risk of pulmonary embolism and endometrial cancer are adverse effects described as 
being associated with treatment with tamoxifen [32]. Raloxifene, a second generation SERM, has also 
been assayed for BC prevention. A comparative clinical trial between tamoxifen and raloxifene has 
Figure 1. The basic enzymatic mechanisms involved in the transformation of steroids in the normal
ma mary gland and in breast cancer tissue. Melatonin acts as a selective estrogen enzyme modulators
(SEEM) by inhibiting the expression and activity of the enzymes (labeled in red) responsible for the
formation of biologically active estrogens from steroids with low biological activity, whereas it increases
the expression and activity of the enzymes (l beled in green) involved in the transformatio of estrogens
into their inactive sulfoconjugates. In breast ancer tissue, the local productio of steroids is biased
towards production of the more active forms (wide arrows).
2.2. Antiestrogenic Drugs
In the last 20 years, two ain fa ilies of r gs hich are able to interact with the synthesis and
actions of the estrogens were developed an are now used for the prevention and treatment of ER+ BC.
Selective estrogen receptor modulators (SERMs) are drugs that are able to bind to the ER and act as
estrogen antagonists in the uterus and breast. Tamoxifen, a first generation SERM, is probably the
most widely used drug in BC prevention. The results of different clinical trials in women classified as
having a high risk for BC showed that treatment with tamoxifen (20 mg/day) for 5 years significantly
reduced the incidence of ER+ BC, but not of ER− tumors [4,31]. Flushes, as well as increased risk of
pulmonary embolism and endo etrial cancer are adverse effects described as being associated with
treatment with tamoxifen [32]. Raloxifene, a second generation SERM, has also been assayed for BC
prevention. A comparative clinical trial between tamoxifen and raloxifene has shown that, although
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the first appears to be more effective than the second, in terms of reducing BC risk, the undesirable
side effects related to tamoxifen, particularly the increased risk of endometrial cancer, are lower in
women treated with raloxifene [33].
A second family of antiestrogenic drugs includes the selective estrogen enzyme modulators
(SEEMs), that is to say, drugs that do not bind to the ER but instead modulates the activity of
the enzymes involved in the conversion of androgens into estrogens, as well as those involved
in the interconversion between inactive (conjugated) and active (unconjugated) steroids. Exemestrane
and anastrozole are drugs belonging to the SEEM family, and both have antiaromatase properties.
Their efficacy in reducing the risk of BC in postmenopausal women has been demonstrated in different
clinical trials [5]. Their main negative side effect is a potential increase in osteoporosis as a consequence
of estrogen’s depletion [34].
2.3. Antiestrogenic Properties of Melatonin
Interestingly, melatonin acts as a SEEM and inhibits the expression and activity of P450 aromatase,
type I 17β-hydroxysteroid dehydrogenase and estrogen sulfatase, that is to say, the expression of the
enzymes responsible for the formation of biologically active estrogens from steroids (androgens and
estrogens) with low biological activity (Figure 2). Furthermore, melatonin increases the expression
and activity of estrogen sulfotransferases, thus favoring the transformation of estrogens into their
inactive sulfoconjugates (Figure 2) [35–43]. Melatonin has also been shown not only to possess SEEM
properties but also to act as an SERM [35–43]. In MCF-7 human breast cancer cells, the melatonin
binding to the MT1 and MT2 receptors present in the membranes of these cells [44–46] down-regulates
the expression of ER-α and inhibits the binding of the estradiol-ER complex to the estrogen response
element in DNA (Figure 2) [47,48].
2.4. Melatonin Potentiates the Efficiency of SEEM and SERM Drugs and Reduce Their Side Effects
In addition to its simultaneous properties functioning as both a SEEM and a SERM, experimental
data has also revealed that melatonin increases the sensitivity of MCF-7 cells to the effects of
antiestrogens such as tamoxifen [49], and that pretreatment with melatonin increases the reduction of
aromatase expression and the activity of cells exposed to aminoglutethimide, an anti-steroid drug [50].
This evidence supports the idea of using melatonin to enhance the effects of conventional SEEM and
SERM drugs (Figure 2).
Furthermore, melatonin could be also useful for reducing or suppressing some of the side effects
of conventional antiestrogens (Figure 2). In this regard, it has been demonstrated, in animal models,
that melatonin reduces the hepatotoxicity of the aromatase inhibitor letrozole [51]. A recent patent
(US8785501; 2014, from Witt-Enderby et al., Duquesne University of the Holy Spirit, USA) reports
a tamoxifen-melatonin hybrid ligand for BC treatment. In mice, the administration of the hybrid
compound N-desmethyl-4-hydroxytamoxifen-melatonin showed anticancer effects without the uterine
hyperproliferation observed after treatment with tamoxifen alone. These results have not yet been
published in ordinary scientific journals.
Interestingly, the possible association of melatonin with antiaromatases could reduce the risk
of osteoporosis described with treatment with this family of drugs. Melatonin promotes osteoblast
proliferation and the synthesis of osteoprotegerin, a member of the tumor necrosis factor receptor
(TNFR) superfamily. This protein inhibits the differentiation of osteoclasts by preventing the binding
of osteoclast differentiation factor (ODF) to receptor activator of NK-κB ligand (RANK) on the
differentiating osteoclasts. In this way, melatonin could cause an inhibition of bone resorption and
an increase in bone mass [52–55]. In addition, the osteoclastic activity generates free radicals that
induce bone degradation and resorption [56]; melatonin may reduce the osteoclastic activity by
neutralizing free radicals and stimulating the activity of antioxidant enzymes [56,57]. The usefulness
of melatonin in the treatment of osteoporosis has been analyzed in several clinical trials carried out in
postmenopausal women with osteopenia. Administering melatonin to these women (1–3 mg/day for
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6–12 months) improved bone mineral density and decreased the risk of fractures [58,59]. The role of
melatonin in bone metabolism is also supported by indirect data such as the association between the
incidence of hip and wrist fractures and nightshift work (which suppresses melatonin production) in
postmenopausal nurses [60], and between the increased incidence of osteoporosis and the decrease of
melatonin production with age [61].
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Figure 2. Summary of the evidence supporting the role of melatonin as a possible adjuvant therapy with
other selective estrogen enzyme modulators (SEEM) and selective estrogen receptor modulators (SERM)
drugs to reduce the risk of breast cancer. Melatonin not only has both SEEM and SERM properties,
it also enhances the effectiveness of other antiestrogenic drugs while reducing or preventing their
unwanted side effects. Abbreviations: 17β-HSD, 17β-hydroxysteroid dehydrogenase; ERα, estrogen
receptor alpha; E, estradiol; ERE, estrogen response element.
A meta- nalysis of 51 epidemiol gical studies comprising more than 150.00 women, carried
out by the Group on Hormonal Factors in Breast Cancer [62] concluded that
hormon r placement therapy (HRT) after menop use was associated with an inc eased risk of
BC. The ssociation of melatonin with conve tional HRT (estrogens + prog sterone) to preven the risk
of BC was paten d a few y ars ago (US8618083; 2013, from Witt-Enderby et al., Duqu sne
University of the Holy Spirit, USA). The patent documents describe experiments carried out on mice,
concluding that asso iating melatonin with HRT significan ly creases the late cy a d decreases the
incide ce of mamm ry cancer.
In conclusion, the above-mentioned data strongly supports the pos ible benefits of th association
of melatoni with conventional antiestrogens s well as HRT to reduce the risk of BC, and clinical
tri ls to a alyze the efficiency of these cotreatment are encouraged.
3. Melatonin for Reduction of BC Risk due to Environmental Factors
The “classical” risk factors for breast cancer, that is to say, genetic mutations, reproductive
history, obesity, alcohol consumption, radiation and sedentary lifestyle do not explain all the potential
situations of increased risk of mammary carcinogenesis. The link between BC risk and environmental
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factors is a subject of growing relevance [63]. There is one environmental factor that, in our opinion
deserves special consideration: the chronodisruption induced by the exposure to light-at-night (LAN),
particularly short wavelength light (i.e., blue-light). The reason is the growing number of individuals
involved in nocturnal shift work. A second group of environmental factors related to BC risk includes
chemical contaminants present in food, pharmaceutical agents and cosmetics, or due to occupational
exposures, etc. [63]; especially interesting are those environmental contaminants with estrogenic
properties, known as xenoestrogens.
3.1. Melatonin Reduces BC Risk from Exposure to Light-at-Night (LAN) Producing Chronodisruption.
The Shift Work
Circadian rhythm disruption induces alterations in one hallmark of cancer, cell division, thus
contributing to cancer progression, and the pharmacological modulation of proteins related to clock
genes is being considered as a possible strategy for cancer treatment [64,65]. Chronodisruption from
LAN represents a factor for BC risk that could be reduced by melatonin (Figure 3).
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Figure 3. The administration of melatonin could reduce the breast cancer risk associated with
chronodisruption caused by exposure to light at night, such as occurs in nocturnal shift workers.
The exogenous melatonin restores the decreased circulating levels of the endogenous hormone, caused
by nocturnal light, and regulates the function of the circadian system.
That LAN increases the rate of growth of mammary tumors has been solidly established in
experiments carried out in rodents with chemically induced tumors or xenografts of cancer cells [66,67].
Furthermore, mutant mice prone to developing mammary tumors, increased their risk of developing
such tumors when exposed to chronically alternating light cycles simulating a shift work [68].
The association between shift work including night work and the increased risk of different
kinds of cancer is supported by numerous studies [64,69–71], although the mechanisms underlying
this relationship are still under study. The risk of BC increases with the number of years devoted
to shift work, with an estimated 16% risk increase for every 10 years [71]. The potential impact of
shift work in breast cancer has been estimated at a population attributable fraction of 5.7% [72].
Epidemiological studies, despite some controversies, support the relationship between long-time
night shift work and an increased risk of breast cancer [63]. The International Agency for Research
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on Cancer (IARC) classified night shift work that involves circadian disruption as a probable human
carcinogen (group 2A) [73]. Based on this classification, the National Board of Industrial Injuries
in Denmark has recognized BC as an occupational disease, in women that had been doing night
shift work for at least one day per week over 20 or more years. Consequently, these women, mainly
nurses and flight attendants, received an economical compensation from the Danish government [74].
There are, however, discrepancies about the carcinogenic effects of nocturnal work, and several
epidemiological studies conclude that night shift work has little or no effect on breast cancer
incidence [75]. These discrepancies may be related to methodological differences between the studies,
due to the complexity of this kind of analysis [63]. As an example of this complexity, a recent publication
about a survey carried out in the Canadian province of British Columbia, comprising 30,700 shift
workers at 88 companies described ¡more than 400 different shift work systems¡ [76]. To these
variables, others which are dependent on the workers’ particular circumstances introduce even more
complexity: the age of the women, their reproductive status, the duration of exposure to nocturnal
light, the subtypes of breast cancer, etc. The most recent published review on this subject concluded
that there is a tendency toward an increased risk of BC among women after 20 or more years of shift
work or even after shorter periods involving many consecutive shifts [77]. Interestingly, the authors of
this review conclude that: “evidence-based preventive interventions are needed” [77].
The two most widely accepted explanations for the biological effects of LAN in elevated BC
risk are: the light-induced inhibition of melatonin secretion, with the subsequent loss of the SEEM
and SERM effects of this neurohormone; and alterations to the circadian system (chronodisruption)
induced by exposure to nocturnal light [15,39–42,78–84].
Regarding the influence of decreased melatonin secretion, a relationship between low plasma
melatonin concentration and breast cancer was described as early as 1978 by Cohen et al. [85]; women
with ER+ breast adenocarcinomas had nocturnal plasmatic concentrations of melatonin significantly
lower than both healthy women and women suffering ER-breast cancer. These authors coined the
expression "relative hyperestrogenism" to define the hormonal situation of women with low melatonin
secretion, whatever its cause. Postmenopausal women working at night have elevated serum estradiol
levels and a significant decrease in urinary excretion of 6-sulfatoxymelatonin (aMT6s), a metabolite of
melatonin that serves as an indicator of melatonin secretion [86–88].
The cell cycle is controlled by the circadian system, and the progression through its different
stages occurs at specific times of the night/day cycle. Although the body’s central clock, situated in
the suprachiasmatic nucleus of the hypothalamus is responsible for the synchronization of the entire
circadian system, peripheral clocks located in almost all cells assume important regulatory functions
such as control of the cell cycle. The coupling between the cellular clocks and the cell cycle is the
key to explaining the relationship between chronodisruption and cancer [89,90]; the disruption of the
circadian rhythms induced by LAN can cause alterations in the cell cycle and lead to the development
of tumors [91,92]. In a recent study [93], carried out with a rat model with ER+ MCF-7 tumor xenografts,
LAN not only increased the rate of tumor development but also conferred resistance to tamoxifen
therapy as well as to chemotherapeutic treatment with doxorubicin [94]. A putative role for the CLOCK
gene in the development of breast cancer in shift workers has been proposed [95], and epidemiological
studies carried out involving shift working women have shown a relationship between breast cancer
susceptibility and polymorphisms in CLOCK, BMAL1, BMAL2 and NPAS2 clock genes [96,97].
The administration of melatonin (1–10 mg/day) to night shift workers has been widely assayed
as a way to ameliorate the body’s adaptation to nocturnal work or to lessen insomnia during the
day [98–100]. However, despite the experimental and epidemiological evidence regarding the role of
LAN in mammary carcinogenesis, the benefit of melatonin supplementation in women working at
night is still yet to be assessed.
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3.2. Melatonin and BC Risk due to Exposure to Xenoestrogens like Cadmium (Cd).
Among the environmental factors with possible incidence in BC risk, the role of chemical
contaminants is a matter of discussion, although there is general agreement that environmental
estrogen-like compounds (xenoestrogens) could be related to the onset and development of BC [101].
Currently, more than 160 xenoestrogens potentially involved in BC development have been
identified [102]. The term metalloestrogens refers to several metals which are able to bind and activate
ERα thus mimicking the actions of endogenous estrogens [103]. In this review, we have focused our
interest on the metalloestrogen, cadmium (Cd), for three reasons: it was designated as a Group 1
human carcinogen in 1993 by the IARC [104]; its implication in health outcomes like BC has been
recently confirmed by different studies [105,106]; there is consistent data concerning melatonin’s role
against Cd’s effects [107] (Figure 4).
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experiments carried out in rats have demonstrated that chronic melatonin consumption prevents 
the effects of obesogenic diets [142]. Furthermore, in ovariectomized rats, used as a model of 
menopause, melatonin decreased food intake and partially prevented the increase of BW observed 
in control animals after suppression of ovarian function [143]. Several clinical trials have confirmed 
the usefulness of melatonin for obesity treatment. In one of these, a randomized, double-blind, 
placebo-controlled study in postmenopausal women treated with either melatonin (1–3 mg nightly) 
or placebo for 1 year, a significant decrease of fat mass was observed, as well as an increase of lean 
mass in the melatonin group compared to placebo [144]. More recently, in a survey, conducted with 
Figure 4. Cadmium, a metalloestrogen, increases the risk of breast cancer by stimulating cell proliferation
due to its estrogenic properties, as well as by producing oxidative stress through mitochondrial damage.
Melatonin could reduce the risk of breast cancer in individuals exposed to Cd from contaminated food,
smoke, or occupational hazards. Melatonin, acts as a specific inhibitor of Cd-induced ERα-mediated
transcription in estrogen response elements. Furthermore, melatonin downregulates the hTERT
expression induced by Cd and increases the synthesis of metallothioneins, which are proteins involved
in Cd detoxification. Moreover, melatonin prevents against Cd-induced oxidative stress.
Cd is naturally present in soils, sediments, seawater, plants, and animals and is a food-chain
contaminant. An individual’s environmental exposure to Cd depends on dietary sources but also
from tobacco smoke (a pack of cigarettes contains about 2–4 µg of Cd) [106]. Occupational exposure
to Cd is significant in industrial processes such as: mining nd processing of zinc, c pper and lead
ores, smelting, galva izing, electroplating, th manufacture of pigments/paints/sealants and plastic
stabilizers, and manufacturing photovoltaic devices and n ckel/cadmium batteries. Due to its long
biological half-life Cd accumul tes in the b dy [108]. A survey carried out in the USA comprising
the period 1999–2008 revealed a Cd exposure prevalence of 94–98% in the non-smoker population
(age ran 20–85 year ) and 96–99% smokers [109]. Be ause of this high exposu e prevalence,
any increase in risk of dis ase from Cd would result in a large numbe of affected individuals [106].
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Although the kidneys are the organs most affected by Cd exposure, epidemiological studies have
demonstrated that this metal can increase the risk of BC [105,110–113]. The concentration of Cd in the
blood [114] as well as in the urine (a measure of cumulative lifetime Cd) of BC patients is significantly
higher than in healthy controls [115–118], and a positive correlation between Cd content in breast
tumor tissue and the histological type of tumor, its size, grading and progesterone receptor status,
has been described [115,119]. In Japanese women, elevated dietary intake of Cd has been associated
with ER+ breast cancer [120]. Furthermore, it has recently been described that in utero exposure to
Cd increases stem/progenitor cells, cell density, and expression of ERα, thereby constituting a risk
factor for BC development [121]. There are, however, other studies that showed no association between
urinary concentration of Cd and risk for development of BC [122,123].
There are two basic explanations for the effects of Cd on the mammary gland. One, is related to
the estrogenic effects of this metal. Cd increases the in vitro proliferation of ER+ breast cancer cells
as well as the expression of estrogen-regulated genes, and increases signaling by ERK1/2 and Akt
pathways [124,125]. In vivo, Cd activates the genomic and non-genomic ER pathways in mammary
glands [126]. The second reason for the damaging effects of Cd is related to its ability to induce
oxidative stress. Although Cd does not produce radicals in Fenton type reactions, it induces oxidative
stress through the reduction of antioxidative defenses as well as by the production of reactive oxygen
species through mitochondrial damage [127].
Melatonin exerts remarkable actions against the estrogenic effect of Cd. In MCF-7 human BC cells,
melatonin prevents cell proliferation by acting as a specific inhibitor of Cd-induced ERα-mediated
transcription in both, estrogen response elements and AP1-containing promoters [128]. Furthermore,
melatonin down-regulates the Cd-induced expression of hTERT, the telomerase subunit main
determinant of its enzyme activity [129]. In vivo, melatonin prevents the estrogenic effects of Cd
on mice mammary glands and uterus [130]. Melatonin has also been shown to induce the expression of
metallothioneins [131]. These are intracellular low molecular weight (6–7 kDa) cysteine-rich proteins
ubiquitous in eukaryotes, and are involved in detoxification mechanisms against Cd [127], and
have been linked to the prognosis of BC [132]. Moreover, numerous studies have already evidenced
melatonin’s role in protecting against Cd-induced oxidative stress [133,134]. This data should serve to
recommend the use of melatonin for individuals who frequently encounter Cd, due to occupational
hazards, or for those residing in geographic areas with high levels of contamination, as a prophylaxis
against the increased risk of BC from exposure to this metalloestrogen.
4. Melatonin, Obesity and BC Risk
Epidemiologic studies included in the Women’s Health Initiative Observational Study have
concluded that generalized obesity represents an important risk factor for breast cancer among
postmenopausal women who have never received HRT, in comparison with slimmer women [135–137].
Body weight (BW) gain, as well as a longer period of time spent being obese or overweight are also BC
risk factors in these women [138,139]. The association between BW gain and mutations of BRCA genes
increases the risk of BC inherent to the genetic cause [140]. This is important data, since obesity or being
overweight is one of the most common medical problems in developed countries, and worldwide
obesity has more than doubled since 1980, now affecting about 39% of the global population [141].
There are multiple links between obesity and BC. We are going to consider those potentially susceptible
to responding to melatonin treatment (Figure 5).
Obviously, the prevention of obesity is the first way to avoid the BC risk related to being
overweight. Melatonin should be considered as a tool for obesity management. Various experiments
carried out in rats have demonstrated that chronic melatonin consumption prevents the effects of
obesogenic diets [142]. Furthermore, in ovariectomized rats, used as a model of menopause, melatonin
decreased food intake and partially prevented the increase of BW observed in control animals
after suppression of ovarian function [143]. Several clinical trials have confirmed the usefulness
of melatonin for obesity treatment. In one of these, a randomized, double-blind, placebo-controlled
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study in postmenopausal women treated with either melatonin (1–3 mg nightly) or placebo for 1 year,
a significant decrease of fat mass was observed, as well as an increase of lean mass in the melatonin
group compared to placebo [144]. More recently, in a survey, conducted with thirty obese persons
(BMI ≥ 30 kg/m2) participants were randomly treated with melatonin (10 mg/day) or placebo for
30 days, combined with caloric restriction. A significant reduction in BW was observed in obese
patients treated with melatonin in comparison with those receiving placebo [145]. Interestingly, it has
been theorized that the protective effect of exercise by decreasing BW and, consequently reducing
the BC risk dependent of this factor, may operate, at least in part, through an increase of melatonin
production induced by the exercise [146]. Sleep deprivation has also been considered among the causes
of obesity [147–149]. The deficiency of melatonin secretion, as a consequence of sleep loss, is among
the links between obesity and sleep deprivation [150,151]. There is consistent evidence supporting the
beneficial effects of melatonin supplementation for treatment of obesity due to sleep deficit as well as
for treating its related complications [151].
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Figure 5. The increased breast cancer risk associated with obesity is related to factors such as: a
low concentration of sex hormone-binding globulin (SHBG), which increases the bioavailability of
sex steroids; an enhanced expression of aromatase, and the subsequent increase of local synthesis of
estrogens; an elevated secretion of leptin by white adipose tissue (WAT) that stimulates cell proliferation;
a low conce tration of adiponecti , an a i okine that inhibits cell proliferation and angiogenesis a
induces apoptosis; the development of insulin resista ce, with an elevated insulin blood concentratio
which induc s the release of growth factors (IGF-1), stimulating cell proliferation. Melatonin, stimulat s
adiponectin secretion; i hibits aromatase expression and preve ts in ulin resistanc . Furthermore,
melatonin reduces body weight gain, diminishing obesity.
In postmenopausal women ovarian synthesis of estrogens is replaced by local synthesis in
peripheral tissues including mammary glands. The expression of aromatase, the enzyme involved
in the synthesis of estrogens via aromatization of the adrenal androgens, is present in mammary
adipose tissue of normal and tumoral glands [152]. One of the most deleterious consequences
of obesity in postmenopausal women is the increased aromatase expression, responsible for
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stimulating the synthesis of estrogens that, in breast tumors, can reach concentrations 10-fold higher
than in blood [153]. Additionally, obese postmenopausal women show decreased levels of sex
hormone-binding globulin (SHBG) a protein that, in the bloodstream, binds sex steroids and regulates
their bioavailability [154,155]. The elevated local concentration of estrogens in mammary tissue of
obese women is the cause of tumor initiation and progression [156]. As commented in a previous
section of this review, melatonin, due to its SERM and SEEM properties reduces estrogen levels and
could be used as a preventive measure for lowering BC risk in obese women [35–50].
Being overweight or obese is a result of an excessive accumulation of fat in white adipose tissue
(WAT) with hyperplasia and hypertrophy of adipocytes, and the development of a state of chronic
inflammation of the WAT. In addition to the storing triglycerides, WAT is the source of bioactive
molecules globally termed as adipokines, which have been correlated with the development of
BC [157,158]. Among the adipokines, decreased levels of adiponectin and increased concentrations of
leptin are associated with BC [157,159].
Adiponectin, whose levels are inversely correlated with adiposity, exerts direct growth-inhibitory
effects on tumor cells by inhibiting cell proliferation and angiogenesis, and upregulating
apoptosis [160]. The levels of this adipokine are lower in BC patients [157,158] and this fact would
explain the increased BC risk in postmenopausal obese women [145]. In vitro, adiponectine inhibits
proliferation of MCF-7 cells [161]. Several experimental studies in rodents have described a stimulatory
effect of melatonin in adiponectin secretion [162,163]. In humans, melatonin (10 mg/day) significantly
increased the adiponectin levels, facilitating BW reduction and preventing the oxidative stress in the
initial stages of weight loss [145]. These results support the use of melatonin in the treatment of obesity
and the reduction of the risk of BC associated with being overweight.
Regarding leptin, its concentration is increased in the obese, reflecting the amount of fat in the
body. In mammary glands, leptin is synthesized in preadipocytes, adipocytes and epithelial cells [164].
This hormone, is involved in the normal development of mammary glands and lactation [165], but also
stimulates cell proliferation, and invasiveness in breast cancer tissue [166], where its levels are higher
than in normal breast tissue [167] The stimulatory effects of leptin on BC growth occurs in different
ways including the activation of the ER [158], upregulation of VEGF, an increase in aromatase activity,
or increase in telomerase activity [168–171]. A recent review of the published experimental studies
concerning the interrelationship between melatonin and leptin was inconclusive, since both a lack
of melatonin effects on leptin secretion as well as melatonin-induced increases or decreases of leptin
levels were described. The reviewers attributed these discrepancies to variations in the experimental
designs [151]. In postmenopausal women leptin levels were not altered by the daytime administration
of melatonin [172]. These facts, contrary to that which happens with adiponectin, do not support any
direct effect of melatonin on leptin secretion. However, melatonin’s effects against the mechanisms
involved in the leptin-induced carcinogenesis supports its use in reducing the BC risk associated
with obesity.
Obese persons become insulin resistant (IR), as a part of the metabolic syndrome (MS). This IR
is due to the effects of some of the adipokines such as tumor necrosis alpha, interleukine-6 or
resistine [173]. Another hormonal factor that links obesity and breast cancer is the high circulating
levels of insulin in obese women, as a consequence of the increased pancreatic synthesis to compensate
for their insulin resistance [171]. Insulin increases the proliferation of ER+ MCF-7 cells (but not of
ER− breast cancer cells) by increasing the release of growth factors that stimulate mitosis and inhibit
apoptosis [171,174]. A meta-analysis of 17 prospective studies carried out in 12 countries concluded
that the circulating concentration of IGF-1 is positively associated with the risk of ER+ BC in both
pre and postmenopausal women [174]. The usefulness of melatonin for the treatment of MS has been
widely demonstrated in animal models [175] as well as in clinical trials showing that administration of
melatonin decreases blood glucose levels and decreases IR [144,176–179].
Recently, it has been shown that the oral antidiabetic drug metformin, used in the treatment
of type 2 diabetes, has in vitro antiproliferative effects in different breast cancer cells lines [180],
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and previously it was observed that patients treated with metformin showed a 31% reduction in the
incidence of different cancers including BC [181]. Consequently, metformin is being considered as
a drug to aid in BC prevention in obese women with IR [182–184]. In this regard, it is remarkable that
several experimental studies in animal models of BC have concluded that the association of melatonin
and metformin inhibited mammary tumor growth by stimulating apoptosis. These results suggest the
possible value of administering melatonin supplements in patients treated with metformin to reduce
the incidence of breast cancer [185–187].
5. Conclusions
In this review we have summarized the evidence in favor of the possible use of melatonin as
an adjuvant therapy for individuals with risk factors for BC. One conclusion is that experimental
studies provide results which support the value of melatonin as an oncostatic drug for reducing the risk
of ER+ breast cancer. The antiestrogenic effects of melatonin (as SEEM and SERM); the additive results
of its association with conventional antiestrogenic drugs (tamoxifen, raloxifen, etc), improving their
positive effects while mitigating or preventing their unwanted side effects; its antioxidant properties;
its effects in obesity and associated metabolic disorders; and its properties as a chronobiotic agent,
countering the effects of exposure to LAN, these are all arguments that, together with its lack of
toxicity, strongly recommend the realization of clinical trials to evaluate whether this basic knowledge
is applicable to programs for reduction of BC risk.
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